Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $36.20

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have been given an average recommendation of “Moderate Buy” by the eleven research firms that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.11.

Several brokerages have issued reports on ANAB. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Wells Fargo & Company boosted their target price on AnaptysBio from $40.00 to $51.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. lowered their target price on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Truist Financial lowered their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, HC Wainwright restated a “neutral” rating and issued a $19.00 target price on shares of AnaptysBio in a research note on Tuesday, February 4th.

AnaptysBio Trading Down 13.0 %

Shares of AnaptysBio stock opened at $14.64 on Tuesday. The business’s fifty day simple moving average is $16.02 and its 200 day simple moving average is $24.46. The firm has a market capitalization of $445.48 million and a P/E ratio of -2.41. AnaptysBio has a 12 month low of $12.21 and a 12 month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($1.61) by $0.89. The business had revenue of $43.11 million for the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Analysts predict that AnaptysBio will post -6.08 EPS for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 33.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ANAB. Fairmount Funds Management LLC purchased a new position in shares of AnaptysBio in the 4th quarter valued at approximately $24,050,000. Boxer Capital Management LLC purchased a new position in shares of AnaptysBio in the 4th quarter valued at approximately $17,212,000. Sanofi purchased a new position in shares of AnaptysBio in the 4th quarter valued at approximately $10,882,000. FMR LLC lifted its stake in shares of AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after purchasing an additional 438,557 shares during the period. Finally, Soleus Capital Management L.P. purchased a new position in shares of AnaptysBio in the 4th quarter valued at approximately $5,481,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.